Multiple myeloma treatment market seen reaching $14.6 billion by 2033

By AI, Created 11:06 AM UTC, May 20, 2026, /AGP/ – The global multiple myeloma treatment market is forecast to grow from $8.4 billion in 2026 to $14.6 billion by 2033, according to Persistence Market Research. Growth is being driven by aging populations, CAR-T and other targeted therapies, and rising investment in cancer research, while high treatment costs and limited specialist centers remain barriers.

Why it matters: - The market’s growth signals rising demand for therapies that can treat multiple myeloma more precisely and extend patient survival. - Expanding access to advanced oncology care could reshape treatment pathways in North America, Europe and fast-growing Asia Pacific markets. - The forecast also points to continued investment opportunities for drugmakers, biotech firms and care providers working in immunotherapy and targeted therapy.

What happened: - Persistence Market Research projects the global multiple myeloma treatment market will reach US$ 8.4 billion in 2026 and US$ 14.6 billion by 2033. - The forecast implies an 8.2% compound annual growth rate during the period. - The report says the market is being pushed by rising disease prevalence in aging populations and stronger demand for innovative therapies. - The research was released in London on May 5, 2026. - Download the sample report.

The details: - Targeted therapy is projected to hold the largest revenue share at nearly 30% in 2026. - Immunotherapy is expected to be the fastest-growing treatment type from 2026 through 2033. - CAR-T therapies and monoclonal antibodies are central to that growth. - North America is projected to account for about 38% of the market in 2026. - Asia Pacific is forecast to be the fastest-growing regional market. - The report links Asia Pacific’s growth to private healthcare investment and digital health adoption. - The market is described as moderately consolidated, with large pharmaceutical companies competing through R&D, partnerships and differentiated portfolios. - In the U.S., new multiple myeloma cases are projected to reach 36,110 in 2025. - The disease largely affects people age 65 and older. - The U.S. National Cancer Institute allocated more than US$ 7.2 billion in FY 2025 to cancer research, including multiple myeloma studies. - The report says that funding lowers barriers for drugmakers and speeds clinical trials. - Major market segments include chemotherapy, immunotherapy, targeted therapy, stem cell transplant and radiation therapy. - Drug classes covered in the market include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, CAR-T cell therapy, bispecific antibodies and corticosteroids plus chemotherapy agents. - The report also breaks the market out across North America, Europe, East Asia, South Asia and Oceania, Latin America, and the Middle East and Africa.

Between the lines: - The report’s growth outlook reflects a market moving toward higher-value, more complex therapies that can improve outcomes but also raise cost and access challenges. - Limited access to specialized treatment centers remains a key constraint, especially for CAR-T therapy and stem cell transplants that require advanced infrastructure and trained teams. - High prices, reimbursement differences and logistics burdens continue to slow adoption in some regions. - Personalized medicine and digital monitoring tools are becoming more important because they can support adherence, tracking and earlier treatment decisions. - Recent early-2026 research from Emory University, Technical University of Munich and Memorial Sloan Kettering Cancer Center points to continued progress in frontline regimens, CAR-T reactivation and survival gains.

What’s next: - The report expects sustained demand for targeted therapy, immunotherapy and personalized treatment approaches through 2033. - Asia Pacific’s oncology infrastructure buildout and digital health adoption are likely to remain major growth drivers. - Broader market expansion will depend on whether health systems can improve access to advanced therapies and reduce affordability gaps. - Readers can also request customization or checkout the full report.